State-owned Chinese plasma-products maker under China National Biotec Group, producing albumin, immunoglobulin and vaccines.
State-owned Chinese plasma-products maker under China National Biotec Group, producing albumin, immunoglobulin and vaccines.
Plasma products carry the company: albumin and immunoglobulin are extracted from collected blood plasma, so sales depend on how much its licensed collection stations can gather. Hospitals and distributors buy them, with vaccines a smaller line. It sits inside the state-owned Sinopharm group through China National Biotec.
In one line: A state-owned Chinese CSL Behring.
Moat: narrow (regulatory licence, scale). State-backed plasma-collection network under Sinopharm/CNBG with licensed collection stations nationwide.
Headquarters: Beijing, China · Employees: 5,205
Size Beijing Tiantan Biological Products (600161.SS) is a China Health Care company (Biotechnology) with a market value of $3.47B, the 703rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.94 on 18 Nov 2026.
Performance Over six months the shares fell 13.3%, against +1.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 12.8% over the last twelve months (peer median +8.3%); the operating margin is 21.4% (peer median -35.0%).
Valuation It trades at 33.1× forward earnings against a peer median of 29.4× (4th most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.56B | CN¥6.14B | CN¥6.01B | CN¥5.13B | CN¥4.22B |
| Revenue growth | — | +2% | +17% | +22% | — |
| Gross profit | CN¥2.39B | CN¥2.58B | CN¥3.19B | CN¥2.52B | CN¥2.00B |
| EBITDA | n/a | CN¥2.22B | CN¥2.83B | CN¥1.98B | CN¥1.49B |
| Net income | CN¥700M | CN¥1.09B | CN¥1.55B | CN¥1.11B | CN¥881M |
| Free cash flow | CN¥41.3M | -CN¥230M | -CN¥226M | CN¥1.35B | -CN¥206M |
| Capital expenditure | CN¥619M | CN¥606M | CN¥1.07B | CN¥1.08B | CN¥1.35B |
| Total debt | CN¥79.2M | CN¥187M | CN¥59.4M | CN¥147M | CN¥409M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Beijing Tiantan Biological Products 600161.SS | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% |
| Hualan Biological Engineering 002007.SZ | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% |
| Shanghai RAAS Blood Products 002252.SZ | $4.57B | -15% | -22% | 17% | 12.8× | n/a |
| CSL CSL.AX | $63.7B | +102% | -2% | 26% | 21.5× | 6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600161.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.9% | -6.1% | 10th highest of 21 |
| 6-month return | -13.3% | +1.1% | 6th lowest of 21 |
| Distance from 52-week high | -36.1% | -31.6% | 8th lowest of 21 |
| Revenue growth (TTM) | -12.8% | +8.3% | 4th lowest of 16 |
| Operating margin | 21.4% | -35.0% | 2nd highest of 16 |
| Forward P/E | 33.1× | 29.4× | 4th most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 2.2% | 10.8% | 2nd least demanding of 5 |
| Growth delivered (Del g) | +12.5% | +37.0% | 3rd highest of 5 |
| Hurdle (Req g minus delivered) | -10.3 pp | -22.2 pp | 3rd least demanding of 5 |
| ROIC minus cost of capital | +2.4 pp | -10.9 pp | 4th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% | +12.5% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | n/a | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | n/a | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | n/a | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $3.67B | -6% | +12% | -4% | 29.4× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% | -1.8% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% | +9.4% |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% | +70.2% |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | n/a | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 34.5× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 66.6× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | n/a | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |